Publications
Detailed Information
Stereoselective Synthesis of D-5-Homo-4-selenonucleosides as Potent Therapeutic Agents : 효과적인 치료제로서의 D-5-Homo-4-selenonucleosides의 입체 선택적 합성
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | 정낙신 | - |
dc.contributor.author | 최유진 | - |
dc.date.accessioned | 2017-07-19T11:23:45Z | - |
dc.date.available | 2017-07-19T11:23:45Z | - |
dc.date.issued | 2016-02 | - |
dc.identifier.other | 000000133435 | - |
dc.identifier.uri | https://hdl.handle.net/10371/133627 | - |
dc.description | 학위논문 (석사)-- 서울대학교 대학원 : 약학대학 약학과 약품화학전공, 2016. 2. 정낙신. | - |
dc.description.abstract | D-5-Homo-4-selenonucleosides were synthesized from D-5-homo-4-selenoribose using a Pummerer-type condensation. For the stereoselective synthesis of the key intermediate D-5-homo-4-selenoribose, we employed Sharpless asymmetric epoxidation, regioselective epoxide cleavage, and stereoselective reduction of the ketone as the key steps. | - |
dc.description.tableofcontents | I.Introduction 2
II.Results and Discussion 6 1.Retrosynthetic Plan 6 2.Synthesis 7 III.Conclusion 15 IV.Experimental Section 16 1.General Procedures 16 2.Experimental Procedures 17 V.References 40 국문초록 43 | - |
dc.format | application/pdf | - |
dc.format.extent | 1279125 bytes | - |
dc.format.medium | application/pdf | - |
dc.language.iso | en | - |
dc.publisher | 서울대학교 대학원 | - |
dc.subject | D-5’-Homo-4’-selenonucleosides | - |
dc.subject | Sharpless asymmetric epoxidation | - |
dc.subject | Regioselective cleavage | - |
dc.subject | Stereoselective reduction | - |
dc.subject.ddc | 615 | - |
dc.title | Stereoselective Synthesis of D-5-Homo-4-selenonucleosides as Potent Therapeutic Agents | - |
dc.title.alternative | 효과적인 치료제로서의 D-5-Homo-4-selenonucleosides의 입체 선택적 합성 | - |
dc.type | Thesis | - |
dc.description.degree | Master | - |
dc.citation.pages | 43 | - |
dc.contributor.affiliation | 약학대학 약학과 | - |
dc.date.awarded | 2016-02 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.